| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:49 UTC |
|---|
| Update Date | 2022-03-07 02:51:40 UTC |
|---|
| HMDB ID | HMDB0014563 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Miglustat |
|---|
| Description | Miglustat is a drug used to treat Gaucher disease. It inhibits the enzyme glucosylceramide synthase, an essential enzyme for the synthesis of most glycosphingolipids. It is only used for patients who cannot be treated with enzyme replacement therapy with imiglucerase. It is marketed under the trade name Zavesca. Miglustat is now the first and only approved therapy for patients with Niemann-Pick disease type C (NP-C). It has recently been approved for treatment of progressive neurological symptoms in adult and pediatric patients in the European Union, Brazil, and South Korea. |
|---|
| Structure | CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO InChI=1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9-,10-/m1/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| BuDNJ | ChEBI | | Butyldeoxynojirimycin | ChEBI | | Miglustatum | ChEBI | | N-(N-Butyl)deoxynojirimycin | ChEBI | | N-Butyl deoxynojirimycin | ChEBI | | N-Butyl-1-deoxynojirimycin | ChEBI | | N-Butylmoranoline | ChEBI | | NB-DNJ | ChEBI | | SC-48334 | ChEBI | | Zavesca | ChEBI | | Brazaves | Kegg | | N-(N-Butyl)deoxy-nojirimycin | HMDB | | N-Butyldeoxynojirimycin | HMDB | | OGT 918 | HMDB |
|
|---|
| Chemical Formula | C10H21NO4 |
|---|
| Average Molecular Weight | 219.278 |
|---|
| Monoisotopic Molecular Weight | 219.147058165 |
|---|
| IUPAC Name | (2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol |
|---|
| Traditional Name | miglustat |
|---|
| CAS Registry Number | 72599-27-0 |
|---|
| SMILES | CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO |
|---|
| InChI Identifier | InChI=1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9-,10-/m1/s1 |
|---|
| InChI Key | UQRORFVVSGFNRO-UTINFBMNSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as piperidines. Piperidines are compounds containing a piperidine ring, which is a saturated aliphatic six-member ring with one nitrogen atom and five carbon atoms. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Piperidines |
|---|
| Sub Class | Not Available |
|---|
| Direct Parent | Piperidines |
|---|
| Alternative Parents | |
|---|
| Substituents | - Piperidine
- 1,2-aminoalcohol
- Secondary alcohol
- Tertiary aliphatic amine
- Tertiary amine
- Polyol
- Azacycle
- Organic nitrogen compound
- Hydrocarbon derivative
- Primary alcohol
- Organopnictogen compound
- Organic oxygen compound
- Organooxygen compound
- Organonitrogen compound
- Amine
- Alcohol
- Aliphatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aliphatic heteromonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 169 - 172 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 331 g/L | Not Available | | LogP | -0.6 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 1.28 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 10.1415 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 6.1 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 349.0 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 503.5 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 249.4 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 55.6 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 171.5 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 61.3 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 325.6 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 264.4 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 798.4 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 612.4 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 44.8 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 712.1 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 167.6 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 223.8 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 766.3 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 519.6 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 325.5 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Miglustat,1TMS,isomer #1 | CCCCN1C[C@H](O[Si](C)(C)C)[C@@H](O)[C@H](O)[C@H]1CO | 1729.1 | Semi standard non polar | 33892256 | | Miglustat,1TMS,isomer #2 | CCCCN1C[C@H](O)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]1CO | 1713.2 | Semi standard non polar | 33892256 | | Miglustat,1TMS,isomer #3 | CCCCN1C[C@H](O)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]1CO | 1725.3 | Semi standard non polar | 33892256 | | Miglustat,1TMS,isomer #4 | CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO[Si](C)(C)C | 1760.7 | Semi standard non polar | 33892256 | | Miglustat,2TMS,isomer #1 | CCCCN1C[C@H](O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]1CO | 1763.1 | Semi standard non polar | 33892256 | | Miglustat,2TMS,isomer #2 | CCCCN1C[C@H](O[Si](C)(C)C)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]1CO | 1781.6 | Semi standard non polar | 33892256 | | Miglustat,2TMS,isomer #3 | CCCCN1C[C@H](O[Si](C)(C)C)[C@@H](O)[C@H](O)[C@H]1CO[Si](C)(C)C | 1803.8 | Semi standard non polar | 33892256 | | Miglustat,2TMS,isomer #4 | CCCCN1C[C@H](O)[C@@H](O[Si](C)(C)C)[C@H](O[Si](C)(C)C)[C@H]1CO | 1792.3 | Semi standard non polar | 33892256 | | Miglustat,2TMS,isomer #5 | CCCCN1C[C@H](O)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]1CO[Si](C)(C)C | 1817.7 | Semi standard non polar | 33892256 | | Miglustat,2TMS,isomer #6 | CCCCN1C[C@H](O)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]1CO[Si](C)(C)C | 1813.0 | Semi standard non polar | 33892256 | | Miglustat,3TMS,isomer #1 | CCCCN1C[C@H](O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H](O[Si](C)(C)C)[C@H]1CO | 1845.4 | Semi standard non polar | 33892256 | | Miglustat,3TMS,isomer #2 | CCCCN1C[C@H](O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]1CO[Si](C)(C)C | 1874.8 | Semi standard non polar | 33892256 | | Miglustat,3TMS,isomer #3 | CCCCN1C[C@H](O[Si](C)(C)C)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]1CO[Si](C)(C)C | 1901.7 | Semi standard non polar | 33892256 | | Miglustat,3TMS,isomer #4 | CCCCN1C[C@H](O)[C@@H](O[Si](C)(C)C)[C@H](O[Si](C)(C)C)[C@H]1CO[Si](C)(C)C | 1903.2 | Semi standard non polar | 33892256 | | Miglustat,4TMS,isomer #1 | CCCCN1C[C@H](O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H](O[Si](C)(C)C)[C@H]1CO[Si](C)(C)C | 1948.0 | Semi standard non polar | 33892256 | | Miglustat,1TBDMS,isomer #1 | CCCCN1C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](O)[C@H](O)[C@H]1CO | 1985.1 | Semi standard non polar | 33892256 | | Miglustat,1TBDMS,isomer #2 | CCCCN1C[C@H](O)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O)[C@H]1CO | 1961.9 | Semi standard non polar | 33892256 | | Miglustat,1TBDMS,isomer #3 | CCCCN1C[C@H](O)[C@@H](O)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]1CO | 1976.4 | Semi standard non polar | 33892256 | | Miglustat,1TBDMS,isomer #4 | CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO[Si](C)(C)C(C)(C)C | 2011.8 | Semi standard non polar | 33892256 | | Miglustat,2TBDMS,isomer #1 | CCCCN1C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O)[C@H]1CO | 2268.2 | Semi standard non polar | 33892256 | | Miglustat,2TBDMS,isomer #2 | CCCCN1C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](O)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]1CO | 2277.7 | Semi standard non polar | 33892256 | | Miglustat,2TBDMS,isomer #3 | CCCCN1C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](O)[C@H](O)[C@H]1CO[Si](C)(C)C(C)(C)C | 2305.8 | Semi standard non polar | 33892256 | | Miglustat,2TBDMS,isomer #4 | CCCCN1C[C@H](O)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]1CO | 2277.8 | Semi standard non polar | 33892256 | | Miglustat,2TBDMS,isomer #5 | CCCCN1C[C@H](O)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O)[C@H]1CO[Si](C)(C)C(C)(C)C | 2307.0 | Semi standard non polar | 33892256 | | Miglustat,2TBDMS,isomer #6 | CCCCN1C[C@H](O)[C@@H](O)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]1CO[Si](C)(C)C(C)(C)C | 2295.3 | Semi standard non polar | 33892256 | | Miglustat,3TBDMS,isomer #1 | CCCCN1C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]1CO | 2553.4 | Semi standard non polar | 33892256 | | Miglustat,3TBDMS,isomer #2 | CCCCN1C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O)[C@H]1CO[Si](C)(C)C(C)(C)C | 2582.1 | Semi standard non polar | 33892256 | | Miglustat,3TBDMS,isomer #3 | CCCCN1C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](O)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]1CO[Si](C)(C)C(C)(C)C | 2601.5 | Semi standard non polar | 33892256 | | Miglustat,3TBDMS,isomer #4 | CCCCN1C[C@H](O)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]1CO[Si](C)(C)C(C)(C)C | 2595.6 | Semi standard non polar | 33892256 | | Miglustat,4TBDMS,isomer #1 | CCCCN1C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]1CO[Si](C)(C)C(C)(C)C | 2835.9 | Semi standard non polar | 33892256 |
|
|---|
| General References | - Moyses C: Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease. Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):955-60. [PubMed:12803929 ]
- Weinreb NJ, Barranger JA, Charrow J, Grabowski GA, Mankin HJ, Mistry P: Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. Am J Hematol. 2005 Nov;80(3):223-9. [PubMed:16247743 ]
- Wraith JE, Imrie J: New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat. Ther Clin Risk Manag. 2009;5:877-87. Epub 2009 Nov 18. [PubMed:19956552 ]
- McCormack PL, Goa KL: Miglustat. Drugs. 2003;63(22):2427-34; discussion 2435-6. [PubMed:14609352 ]
- Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE: Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol. 2007 Sep;6(9):765-72. [PubMed:17689147 ]
- van Giersbergen PL, Dingemanse J: Influence of food intake on the pharmacokinetics of miglustat, an inhibitor of glucosylceramide synthase. J Clin Pharmacol. 2007 Oct;47(10):1277-82. Epub 2007 Aug 24. [PubMed:17720777 ]
|
|---|